Maddocks advises on key technology acquisition
Maddocks has advised the founder of Brisbane-based company Adopt & Embrace on its purchase by Netherlands-based Microsoft cloud specialist Rapid Circle, backed by private equity firm Mentha Capital
Adopt & Embrace works with companies on change management issues when adopting the Microsoft 365 suite of products. They have worked with major companies such as Youi and Deloitte on large-scale digital projects. The company will continue to operate as Adopt & Embrace and act as Rapid Circle’s adoption and change management unit in Australia.
This is the second strategic acquisition by Rapid Circle in Australia this year – and both times Maddocks advised the company that was acquired. In the previous matter, Maddocks acted for Australian-based Microsoft partner Insync Technology.
Maddocks is a proudly independent Australian law firm that works closely with corporations, businesses and governments throughout Australia and internationally. We advise national and international clients across the education, government, healthcare, infrastructure and technology sectors, from our Canberra, Melbourne and Sydney offices. Our specialist expertise includes dispute resolution and litigation, employment and safety, financial services, franchising and insolvency.
For more information:
Tel: 03 9258 3509
Mobile: 0407 618 058
Maddocks lodges appeal for investors caught in liquidation of online stockbroking platform
Maddocks has lodged appeals in relation to on behalf of investors in the now liquidated Halifax Investments Services.
Maddocks advises Go-To Skincare on partnership with BWX
Maddocks has advised Zoë Foster Blake and co-founders of Go-To Skincare on their sale of 50.1% of their business to BWX.
Maddocks appoints special counsel to healthcare team
Maddocks has appointed Francine Kinkade as a special counsel in the firm’s healthcare team.
Maddocks advises global pharma company on acquisition of Southern Cross Pharma
Maddocks has advised Lupin Limited and its subsidiary Generic Health on the acquisition of Southern Cross Pharma,